Page 83 - 《中国药科大学学报》2026年第1期

第 57 卷第 1 期 葛 姮，等：五氟利多靶向 HSPA6 抑制黑色素瘤生长的作用研究 77
A B C **

Model si-NC+Penfluridol Model 125
800 Penfluridol si-HSPA6 100
si-NC si-HSPA6+Penfluridol Penfluridol 75
Tumor Size Variations compared to 0 day/% 400 si-NC+Penfluridol Mean tumor volume compared to control group/% 50 0
600
si-NC
25
si-HSPA6
si-HSPA6+Penfluridol
si-NC
200
0 si-HSPA6+Penfluridol Model Penfluridol si-NC+Penfluridol si-HSPA6
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
t/d
Figure 7 Tumor growth inhibition induced by penfluridol depends on the presence of HSPA6 ( x ± s,n=5)
A: Tumor growth kinetics [Tumor volumes are shown relative to the tumor volume in mice before treatment (set as "1")]; B: Representative
photographs of excised tumors; C: Terminal tumor volume comparison [Tumor volumes are shown as a percentage relative to the Model group
(set as 100%)]
**P < 0.01
当 HSPA6 表达被抑制时，其对 p53 的影响作用减 sion in breast cancer through induction of reactive oxygen
species and downregulation of sp transcription factors[J]. Mol
弱，进而削弱五氟利多对促凋亡通路的激活效应。 Cancer Ther, 2017, 16(1): 205-216.
综上，五氟利多可显著抑制黑色素瘤细胞的增 [10] Shaw V, Srivastava S, Srivastava SK. Repurposing antipsy-
殖，导致细胞发生 G 期阻滞，诱导细胞发生凋亡， chotics of the diphenylbutylpiperidine class for cancer
1
therapy[J]. Semin Cancer Biol, 2021, 68: 75-83.
其分子机制可能与上调细胞内 HSPA6、p53、p21 的 [11] Lai TC, Lee YL, Lee WJ, et al. Synergistic tumor inhibition via
表达有关。本研究不仅扩大了五氟利多的治疗广 energy elimination by repurposing penfluridol and 2-deoxy-D-
glucose in lung cancer[J]. Cancers (Basel), 2022, 14(11): 2750.
度，还为黑色素瘤的治疗提供新的治疗手段。
[12] Cheikh IA, Hayar B, Ghanem N, et al. Therapeutic targeting of
the pentose phosphate pathway in colorectal cancer using 6-
aminonicotinamide and 5-fluorouracil[J]. Mol Carcinog, 2025,
References
64(7): 1222-1235.
[1] Gosman LM, Țăpoi DA, Costache M. Cutaneous melanoma: a [13] Ranjan A, Gupta P, Srivastava SK. Penfluridol: an antipsychot-
review of multifactorial pathogenesis, immunohistochemistry, ic agent suppresses metastatic tumor growth in triple-negative
and emerging biomarkers for early detection and breast cancer by inhibiting integrin signaling axis[J]. Cancer
management[J]. Int J Mol Sci, 2023, 24(21): 15881. Res, 2016, 76(4): 877-890.
[2] Li J, Yang X, Yin CL, et al. CDKN2A a key gene in copper-in- [14] Arcidiacono P, Ragonese F, Stabile A, et al. Antitumor activity
duced cell death model, influencing melanoma invasion and and expression profiles of genes induced by sulforaphane in hu-
apoptosis[J]. Discov Oncol, 2025, 16(1): 246. man melanoma cells[J]. Eur J Nutr, 2018, 57(7): 2547-2569.
[3] Ung W, Bonavida B. Review article: fecal microbiota transplan- [15] Manjunath P, Stojkovič G, Euro L, et al. Preferential binding of
tation in melanoma: mechanisms-mediated enhancement of an- ADP-bound mitochondrial HSP70 to the nucleotide exchange
ti-tumor immunotherapy[J]. Crit Rev Oncog, 2025, 30(2): 23-35. factor GRPEL1 over GRPEL2[J]. Protein Sci, 2024, 33(11):
[4] Shi YK, Han XH, Zhao Q, et al. Tunlametinib (HL-085) plus e5190.
vemurafenib in patients with advanced BRAF V600-mutant sol- [16] Ranjan A, German N, Mikelis C, et al. Penfluridol induces en-
id tumors: an open-label, single-arm, multicenter, phase I doplasmic reticulum stress leading to autophagy in pancreatic
study[J]. Exp Hematol Oncol, 2024, 13(1): 60. cancer[J]. Tumour Biol, 2017, 39(6): 1010428317705517.
[5] Pavlick AC, Ariyan CE, Buchbinder EI, et al. Society for Im- [17] Williams AB, Schumacher B. p53 in the DNA-damage-repair
munotherapy of Cancer (SITC) clinical practice guideline on process[J]. Cold Spring Harb Perspect Med, 2016, 6(5):
immunotherapy for the treatment of melanoma, version 3.0[J]. J a026070.
Immunother Cancer, 2023, 11(10): e006947. [18] Lossaint G, Horvat A, Gire V, et al. Reciprocal regulation of
[6] Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Im- p21 and Chk1 controls the cyclin D1-RB pathway to mediate
munotherapy of Cancer (SITC) clinical practice guideline on senescence onset after G2 arrest[J]. J Cell Sci, 2022, 135(8):
immune checkpoint inhibitor-related adverse events[J]. J Im- jcs259114.
munother Cancer, 2021, 9(6): e002435. [19] Zhang XL, Yu GZ, Cai L, et al. Wild-type p53 regulates apop-
[7] Villegas-Vazquez EY, Marín-Carrasco FP, Reyes-Hernández tosis of human breast cancer cells[J]. Discov Med, 2024,
OD, et al. Revolutionizing ovarian cancer therapy by drug repo- 36(191): 2445-2453.
sitioning for accelerated and cost-effective treatments[J]. Front [20] Zhou Y, Zhang BW, Wang XD, et al. A network pharmacology
Oncol, 2025, 14: 1514120. approach and experimental validation to investigate the protec-
[8] Kim WJ, Ryu JY, Chang CS, et al. Anticancer effect of the an- tion mechanism of Ganoderma lucidum (Leyss. ex Fr. ) Karst
tipsychotic agent penfluridol on epithelial ovarian cancer[J]. J spore for acute kidney injury through induction of apoptosis via
Gynecol Oncol, 2025, 36(2): e28. p53/Caspase 3 signaling pathway[J]. J Ethnopharmacol, 2025,
[9] Hedrick E, Li X, Safe S. Penfluridol represses integrin expres- 351: 120075.